The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Claims

4 · 1 independent · depth 2

4 granted claims

›1.independentA method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient, wherein said treatment l…+3

Classifications

9 codes

IPC · International Patent Classification

Section A — Human necessities

A61P1/16
A01N43/04
A61K31/70
A61K38/00
A01N37/18

USPC · US Patent Classification

514/4.3514/51514/49514/48

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

1.4 y

522 days filing → grant

Office actions

non-final + final

Responses

1 RCE

Interviews

examiner interview summaries

Examiner

Zachary J Miknis

art unit —

Law firm

Law firm · Log in to unlock

Citations: 681 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

2 priority documents

Priority

10 Oct 2012

earliest claimed

›Priority documents — 2

Type	Document	Date
provisional	US 61711793	10 Oct 2012
related publication	US 20130102526 A1	25 Apr 2013

Litigation

See every case on record — court, docket number, and outcome for each one.

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.